Gabapentin for Parkinsonism: A double-blind, placebo-controlled, crossover trial

American Journal of Medicine

Volumn 102, Issue 1, 1997, Pages 60-66

  Olson, Walter L ^a   Gruenthal, Michael ^a   Mueller, Marguerite E ^a   Olson, William H ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; GABAPENTIN; PERGOLIDE; SELEGILINE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; BRADYKINESIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROMYOGRAPHY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RIGIDITY; TREMOR;

ACETIC ACIDS; ADULT; AGED; AMINES; ANTIPARKINSON AGENTS; CROSS-OVER STUDIES; CYCLOHEXANECARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; ELECTROMYOGRAPHY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; TREMOR;

EID: 0031048102     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00381-6     Document Type: Article

References (42)

1. Weiner WJ, Lang AE. Parkinson's disease. In: Movement Disorders: A Comprehensive Survey. Mount Kisco, New York: Futura; 1989:23-115.
2. Weiner WJ, Lang AE. Other akinetic-rigid and related syndromes. In: Movement Disorders: A Comprehensive Survey. Mount Kisco, New York: Futura; 1989:117-219.
3. Leach JP, Brodie MJ. New antiepileptic drugs - an explosion of activity. Seizure. 1995;4:5-17.
4. Andrews CO, Fischer JH. Gabapentin: a new agent for the management of epilepsy. Ann Pharmacother. 1994;28:1188-1196.
5. McLean MJ. Gabapentin. Epilepsia. 1995;36(suppl 2):S73-86.
6. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al, eds. Recent Development in Parkinson's Disease. Vol 2. Florham Park, New Jersey: Macmillan Health Care Information; 1987:153-163, 293-304.
7. Webster DD. Critical analysis of the disability in Parkinson's disease. Modern Treatment. 1968;5:257-282.
8. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17(5):427-442.
9. Keppel G. Correction for cumulative type I error. In: Design and Analysis: A Researcher's Handbook. 3rd ed. Upper Saddle River, New Jersey: Prentice-Hall; 1991:163-184.
10. Burrows GT, King RB. Gabapentin in essential tremor. Neurology. 1995;45(suppl 4):A187-188. Abstract.
11. Conover WJ. Contingency tables. Practical Non-Parametric Statistics. 2nd ed. New York: Wiley & Sons; 1980:143-212.
12. Tretiakoff C. Contribution l'etude de l'anatomie pathologique du locus niger. University of Paris; 1919.
13. Birkmayer W, Hornykiewicz O. Der L-3,4-dioxyphenylalanin (L-Dopa)-effect bei der parkinson akinese. Wien Klin Wochenschr. 1961;73:787-788.
14. Wolters EC, Tissingh G, Bergmans PL, Kuiper MA. Dopamine agonists in Parkinson's disease. Neurology. 1995;45(3 suppl 3):S28-34.
15. Groves PM, Garcia-Munoz M, Under JC, et al. Elements of the intrinsic organization and information processing in the neostriatum. In: Houk JC, Davis JL, Beiser DG, eds. Models of Information Processing in the Basal Ganglia. Vol 8. Cambridge, Massachusetts: MIT Press; 1995:51-96.
16. Ferre S, O'Connor W, Fuxe K, Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci. 1993;13:5402-5406.
17. Satzinger G, Hartenstein J, Herrmann M, Heldt W. Cyclic amino acids. In: Advanced Organic Chemistry. Vol 260. United States: Warner-Lambert Company; 1977:1-8.
18. Taylor CP. Mechanism of action of new antiepileptic drugs. In: Chadwick D, ed. New Trends in Epilepsy Management: The Role of Gabapentin. London: Royal Society of Medicine Services Limited; 1993:13-40.
19. Satzinger G. Antiepileptics from gamma-aminobutyric acid. Arzneimittelforschung. 1994;44:261-266.
20. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology. 1994;44:S17-22.
21. Bartoszyk GD, Meyerson N, Reimann W, et al. New anticonvulsant drugs. Gabapentin. In: Meldrum BS, Porter RJ, eds. Current Problems in Epilepsy. Vol 4. London: John Libbey; 1986:147-163.
22. Goldlust A, Ti-Zhi S, Welty DF, et al. Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res. 1995;22(1):1-11.
23. Loscher W, Honack D, Taylor CP. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neurosci Lett. 1991;128:150-154.
24. Petroff OAC, Rothman DL, Behar KL, et al. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol. 1996;39(1):95-99.
25. Götz E, Feuerstein TJ, Lais A, Meyer DK. Effects of gabapentin on release of γ-aminobutyric acid from slices of rat neostriatum. Arzneimittelforschung. 1993;43:636-638.
26. Schlicker E, Reimann W, Gothert M. Gabapentin decreases monoamine release without affecting acetylcholine release in the brain. Arzneimittelforschung. 1985;35:1347-1349.
27. Kelly KM, Rock DM, MacDonald RL. Gabapentin does not affect N-methyl-D-aspartate receptor currents or voltage-dependent calcium currents in cultured rodent neurons. Ann Neurol. 1991;30(2):292. Abstract.
28. Rock DM, Kelly KM, MacDonald RL. Gabapentin actions on ligand-and voltage-gated responses in cultured rodent neurons. Epilepsy Res. 1993;16:89-98.
29. Taylor CP. Emerging perspectives on the mechanism of action of gabapentin. Neurology. 1994;44:S10-16.
30. 3H]gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur J Pharmacol. 1993;244:293-301.
31. 3H]gabapentin may label a system-L-like neutral amino acid carrier in brain. Eur J Pharmacol. 1993;247:341-345.
32. 3H]gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol. 1993;244:303-309.
33. Gruenthal M, Mueller ME, Olson WL, et al. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Unpublished data 1996.
34. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993;46:409-427.
35. Meunter MD, Sharpless NS, Tyce GM. Patterns of dystonia (I-D-I and D-I-D) in response to L-dopa therapy for PD. Mayo Clin Proc. 1977;52:163-174.
36. Klawans HL, Goetz C, Bergen D. Levodopa induced myoclonus. Arch Neurol. 1975;32:331-334.
37. Barbeau A. Contributions of levodopa therapy to the neuropharmacology of akinesia. In: Siegfried J, ed. Parkinson's Disease: Rigidity, Akinesia, Behavior. Vol 1. Bern: Hans Huber; 1972:151-174.
38. Barbeau A. The clinical physiology of side effects and long term L-dopa therapy. Adv Neurol. 1974;5:347-365.
39. Kocsis JD, Honmou O. Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neurosci Lett. 1994;169:181-184.
40. Wisden W, Laurie DJ, Monyer H, Seeburg PH. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci. 1992;12:1040-1062.
41. Hausser MA, Yung WH. Inhibitory synaptic potentials in guinea-pig substantia nigra dopamine neurones in vitro. J Physiol (Lond). 1994;479(pt 3):401-422.
42. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substraits for motor, oculomotor, "pre-frontal" and "limbic" functions. Prog Brain Res. 1990;85:119-146.